Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Prostatic Neoplasms 4Neoplasms 3Sarcoma 2Lymphoma, Follicular 2Lymphoma 2Glioblastoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Thrombosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumothorax 1Pituitary Neoplasms 1Philadelphia Chromosome 1Pathologic Complete Response 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Opioid-Related Disorders 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Metastatic Castration-resistant Prostate Cancer 1Meningioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

entinostat 1Pharmacogenomic Testing 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anatomic Stage III Breast Cancer AJCC v8 × Blood Specimen Collection × Clear all
NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
57 enrolled
BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡